Our projectsBrilliant scientists, powerful collaborations. We find and fund projects that are ripe for treating Duchenne now.
Neurobehavioural issues in Duchenne
Tackling learning, behaviour, depression and anxiety.
DMD Care UK
Combating immunity to AAV
Ensuring as many patients as possible can benefit from gene therapy.
A ground-breaking programme for exploring gene therapy for Duchenne.
An alternative to existing steroid treatments for Duchenne.
CRISPR for Duchenne
Gene editing technology to correct mutated dystrophin gene.
Gene therapy for Becker
A microdystrophin gene therapy approach for Becker muscular dystrophy.
Activity monitoring biomarker
KINEDMD: Wearable sensor technology to monitor Duchenne patients’ activity.
A next-generation gene therapy delivery approach.
Grants to support clinical and research staff and facilities
Awards for up-and-coming researchers
Measuring disease progression and response to new treatments.
Dystrophic dogs provide insights into Duchenne research.
This project focuses on targeting inflammation and fibrosis – two key challenges in Duchenne.
Pre-clinical research for drug to target muscle fibrosis.
Non-invasive imaging biomarker
Reducing biopsies and improving dystrophin analysis in Duchenne boys.
Increasing utrophin to compensate for dystrophin.
Our scientific advisory board comprises leading minds in the field: Professor Ronald Cohn, Dr Kevin Campbell, Professor Madeleine Durbeej-Hjalt and Dr James Dowling together with our Honorary Scientific Patron Professor Victor Dubowitz. Read more about their work here. Please contact research [at] duchenne.org.uk for more information about applications.
Your generosity has funded millions of pounds worth of ground-breaking research.
And there is still work to do.